CytoMed Therapeutics Limited (GDTC) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
CytoMed Therapeutics Limited successfully held its annual shareholders meeting, with over 58% of its outstanding shares represented, meeting quorum requirements. Key outcomes included the adoption of financial statements for the 2023 fiscal year and the re-election of Mr. Choo Chee Kong as Director, alongside the ratification of two independent public accounting firms for 2024. All resolutions proposed by the Board of Directors were approved, including the authorization to issue new shares and the approval of Directors’ fees.
For further insights into GDTC stock, check out TipRanks’ Stock Analysis page.
